10 completed, 5 terminated, 4 active not recruiting, 2 recruiting. 15 Phase 2, 5 Phase 1, 5 Phase 3.
Follow PrECOG, LLC.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Tarlatamab and Durvalumab vs. Durvalumab Alone for Limited-Stage-Small Cell Lung Cancer Tarlatamab, Durvalumab - Limited Stage Small-Cell Lung Cancer | Phase 3 | Not yet recruiting | PrECOG, LLC. | 430 | 2027-01-01 | 2026-06-09 |
| Belantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma Arm A: Belantamab Mafodotin, Arm B: Daratumumab Hyaluronidase, Bortezomib - Multiple Myeloma | Phase 3 | Recruiting | PrECOG, LLC. | 500 | 2026-12-01 | 2026-11-06 |
| Phase II Study of Platinum/Etoposide Plus Ivonescimab for Extensive-Stage Small Cell Lung Cancer Ivonescimab 10 mg/kg, Ivonescimab 20 mg/kg - Extensive Stage Lung Small Cell Cancer | Phase 2 | Recruiting | PrECOG, LLC. | 60 | 2026-03-30 | 2026-08-28 |
| Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC Patients Osimertinib, Osimertinib + Chemotherapy - Non Small Cell Lung Cancer, Epidermal Growth Factor Receptor Gene Mutation | Active not recruiting | PrECOG, LLC. | 200 | 2024-09-17 | 2026-09-09 | |
| DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma Durvalumab, Standard Chemotherapy, Ipilimumab and Nivolumab - Mesothelioma, Pleural Mesothelioma | Phase 3 | Completed | PrECOG, LLC. | 214 | 2021-02-18 | 2026-10-22 |
| A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 Study Paclitaxel, Pelareorep, Avelumab - Breast Cancer Metastatic | Phase 2 | Active not recruiting | Oncolytics Biotech | 48 | 2020-06-10 | 2025-01-16 |
| Phase II Study of Bendamustine and Rituximab Plus Venetoclax in Untreated Mantle Cell Lymphoma Over 60 Years of Age Venetoclax, Bendamustine, Rituximab - Mantle Cell Lymphoma | Phase 2 | Completed | PrECOG, LLC. | 33 | 2020-01-13 | 2025-08-11 |
| Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia Gilteritinib, Midostaurin, Daunorubicin - Acute Myeloid Leukemia | Phase 2 | Completed | PrECOG, LLC. | 181 | 2019-12-06 | 2026-07-23 |
| Phase Ib Feasibility Trial of Neoadjuvant Nivolumab/Lirilumab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer Nivolumab, Nivolumab/Lirilumab - Bladder Cancer | Phase 1 | Completed | PrECOG, LLC. | 43 | 2019-03-22 | 2024-09-19 |
| A Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma Ixazomib, Ibrutinib - Mantle-Cell Lymphoma | Phase 1 / Phase 2 | Completed | PrECOG, LLC. | 43 | 2018-08-13 | 2026-06-25 |
| Phase II Venetoclax, Obinutuzumab and Bendamustine in High Tumor Burden Follicular Lymphoma as Front Line Therapy Induction Venetoclax, Maintenance Venetoclax - Follicular Lymphoma, Non-Hodgkin's Lymphoma Follicular | Phase 2 | Completed | PrECOG, LLC. | 56 | 2017-12-27 | 2025-05-23 |
| Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer palbociclib, trastuzumab, pertuzumab - HER-2 Positive Breast Cancer, Estrogen Receptor Positive Breast Cancer | Phase 3 | Active not recruiting | Alliance Foundation Trials, LLC. | 518 | 2017-06-21 | 2026-10-22 |
| Phase II MEDI4736 in Combination With Chemotherapy for First-Line Treatment of Unresectable Mesothelioma Durvalumab - Mesothelioma, Pleural Mesothelioma | Phase 2 | Completed | PrECOG, LLC. | 55 | 2017-06-13 | 2023-07-05 |
| Study of Glembatumumab Vedotin in gpNMB-Expressing, Advanced or Metastatic SCC of the Lung Phase I: Glembatumumab Vedotin, Phase II: Glembatumumab Vedotin - Squamous Cell Carcinoma of the Lung | Phase 1 / Phase 2 | Terminated | PrECOG, LLC. | 13 | 2016-04-10 | 2019-07-16 |
| PALbociclib CoLlaborative Adjuvant Study Palbociclib, Standard Adjuvant Endocrine Therapy - Breast Cancer | Phase 3 | Active not recruiting | Alliance Foundation Trials, LLC. | 5796 | 2015-08-01 | 2026-06-15 |
| Phase II Trial of Nab-Paclitaxel and Gemcitabine for First-Line Treatment of Patients With Cholangiocarcinoma Nab-Paclitaxel and Gemcitabine - Cholangiocarcinoma | Phase 2 | Completed | PrECOG, LLC. | 74 | 2014-12-09 | 2018-10-03 |
| Phase II Randomized Trial Comparing GA101 and Rituximab in Untreated Low Tumor Burden Indolent Non-Hodgkin's Lymphoma Arm A: Rituximab, Arm B: GA101 - Indolent Non-Hodgkin's Lymphoma | Phase 2 | Terminated | PrECOG, LLC. | 32 | 2013-12-01 | 2017-05-05 |
| Study of Fulvestrant +/- Everolimus in Post-Menopausal, Hormone-Receptor + Metastatic Breast Ca Resistant to AI Fulvestrant, Everolimus, Placebo - Metastatic Breast Cancer | Phase 2 | Completed | PrECOG, LLC. | 131 | 2013-05-31 | 2018-05-30 |
| Trial of Eltrombopag During Consolidation Therapy in Adults With AML in Complete Remission Phase I- Cytarabine & Eltrombopag, Phase II- Sequence A, Phase II- Sequence B - Acute Myeloid Leukemia | Phase 1 / Phase 2 | Terminated | PrECOG, LLC. | 15 | 2012-07-01 | 2020-11-03 |
| NEXT: Subsequent Exposure to Tyrosine Kinase Inhibition at Recurrence After Adjuvant Therapy in Renal Cell Carcinoma Axitinib - Renal Cell Carcinoma | Phase 2 | Terminated | PrECOG, LLC. | 3 | 2012-07-01 | 2021-08-12 |
Showing 20 of 22. Sign in to see all of them.
Breast Neoplasms (4) · Carcinoma, Non-Small-Cell Lung (2) · Leukemia, Myeloid, Acute (2) · Lung Neoplasms (2) · Lymphoma, Mantle-Cell (2) · Mesothelioma (2) · Mesothelioma, Malignant (2) · Multiple Myeloma (2) · Small Cell Lung Carcinoma (2) · Bile Duct Neoplasms (1) · Carcinoma, Renal Cell (1) · Cholangiocarcinoma (1) · Jacobs syndrome (1) · Kidney Neoplasms (1) · Leukemia (1)
Carboplatin (3) · durvalumab (3) · Calcium Dobesilate (2) · Cisplatin (2) · Cytarabine (2) · Dexamethasone (2) · Fulvestrant (2) · Lenalidomide (2) · Nivolumab (2) · Pemetrexed (2) · Rituximab (2) · palbociclib (2) · venetoclax (2) · 130-nm albumin-bound paclitaxel (1) · AMG 757 (1)
United States (21) · Australia (3) · Austria (2) · Germany (2) · Italy (2) · New Zealand (2) · Portugal (2) · Spain (2) · Belgium (1) · Canada (1) · France (1) · Hungary (1) · Ireland (1) · Israel (1) · Japan (1)
Craig Portell, MD (2) · Patrick Forde, MD (2) · Angela DeMichele, MD (1) · Anna Nowak, MD (1) · Erica Mayer, MD (1) · Evanthia Galanis, MD (1) · Hillard M Lazarus, MD (1) · Jonathon B Cohen, MD (1) · Joseph Aisner, MD (1) · Joseph R. Mikhael, MD (1) · Michael Gnant, MD (1) · Noah S Kornblum, MD (1) · Petros Grivas, MD, PhD (1) · Rathi Pillai, MD (1) · Ryan Gentzler, MD, MS (1)
PMID 34499875, PMID 12954578, PMID 23689430, PMID 25524798, PMID 29664714, PMID 30032196, PMID 30178032, PMID 30190454, PMID 32476546, PMID 33358660, PMID 33369581, PMID 33460574, PMID 34750557, PMID 34874182, PMID 34995105, PMID 37556775, PMID 38155060, PMID 39849600, PMID 40140172, PMID 40355425, PMID 41604639, PMID 42209393
2014 (1), 2015 (1)